Future Price to Earnings: xenon-pharma.com (XENE)

Brandmark of Xenon Corp (XENE)

Xenon Pharmaceuticals (XENE) develops anti-epilepsy drugs, whose chronic nature guarantees a stable cash flow. The business's forward P/E ratio smooths out market noise, with the 0.00 mark serving as the current indicator. Xenon Pharmaceuticals focuses on selective ion channel blockers for the global CNS market, maintaining its status as a recognized innovator with high physician confidence.

Projected Price to Earnings Ratio: Xenon (XENE) for 07/04/2022 - 11/17/2026

Financial and market metric breakdowns for xenon-pharma.com (XENE)

- company stock exchange capitalization indicators:
Fundamental company valuation:Xenon Pharmaceuticals Inc
Product sample of Xenon Pharmaceuticals

Thanks to unique patents in the field of anti-epileptic drugs, Xenon Pharmaceuticals (XENE) is shielded from pricing pressure, making the bet on future profits pivotal. By analyzing the company's current forward P/E ratio, an investor assesses market yield expectations relative to Fed rates, where a declining multiple signals either an undervalued asset or a risk of liquidity shortages within the sector.

Direct competitors

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Market Cap to Projected Earnings Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Future Price to Earnings|CPRX (Catalyst Pharmaceuticals) - Future Price to Earnings|DNLI (denalitherapeutics.com) - Forward P/E Multiple|Price to Future Earnings Ratio HRMY (Harmony Biosciences Holdings, Inc.)|Forward P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Future Price to Earnings Multiple|Forward P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Price to Expected Earnings Ratio|anavex.com - Forward P/E Multiple|Future Price to Earnings Multiple CBLL (CeriBell, Inc.)|PRTA: Forward P/E Multiple|Price to Future Earnings Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Forward P/E Multiple|omeros.com - Price to Expected Earnings Ratio|Future Price to Earnings Neurogene (NGNE)|Market Cap to Projected Earnings AC Immune SA|Forward P/E Multiple VYGR (voyagertherapeutics.com)|Forward P/E Multiple Neumora NMRA|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)